<DOC>
	<DOCNO>NCT00582855</DOCNO>
	<brief_summary>This study investigate AQW051 patient either mild Alzheimer 's disease amnestic mild cognitive impairment . The effect cognitive impairment measure use validated computerized test measure cognitive function . This study also explore safety tolerability AQW051 patient .</brief_summary>
	<brief_title>Effect AQW051 Patients With Memory Impairment</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Willing able give write informed consent Meet diagnostic criterion either amnestic mild cognitive impairment ( amnestic MCI ) mild Alzheimer 's Disease ( AD ) . Structural brain scan within last 6 month prior randomization indicate underlying disease , particular evidence vascular pathology except normal agerelated white matter/incidental white matter change normal age group . Daily contact primary caregiver/partner Immune therapy target Alzheimer beta amyloid within last 12 month Institutionalized Disability may prevent completion study requirement ( e.g. , blindness , deafness , communication difficulty ) Reported use tobacco product previous 3 month urine cotinine level great 500 ng/ml Past medical history clinically significant electrocardiogram ( ECG ) abnormalities family history ( grandparent , parent , sibling ) prolong QTinterval syndrome History current diagnosis condition specify protocol . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>AQW051</keyword>
	<keyword>Mild Alzheimer 's disease</keyword>
	<keyword>Amnestic Mild Cognitive Impairment</keyword>
</DOC>